Paradigm Biocapital Advisors LP
NEW YORK, NY · CIK 1855655 · 13F filing filed 2025-02-14
SEC-registered investment adviser since 2021 · limited partnership
- Assets managed$4.5bn
- Staff11 · 6 in investment roles
- Main clients (by assets)Private funds 90%
- Private funds2 (2 hedge) · $4.1bn gross assets
- Form ADV · 2026-08-27SEC adviser record
- Legal entityPARADIGM BIOCAPITAL ADVISORS LP (US)
- Kindhedge funds, futures
- Others nearbyNew York, NY
As an employer
- Offices in1 country
- Private fundshedge 2
$2.9bn
reported value
+0.6% vs Q3 2024
28positions
73.6%in top 10
4 new
20 added
3 reduced
7 sold out
vs Q3 2024
Holdings, Q4 2024
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| NUVALENT INC COM | $419.8m14.61% | Added +363.4k |
| ARCELLX INC ACLX | $335.3m11.66% | Added +371.6k |
| ARGENX SE ARGX | $296.0m10.30% | Added +931 |
| REVOLUTION MEDICINES INC RVMD | $286.6m9.97% | Added +1.2m |
| JANUX THERAPEUTICS INC JANX | $188.2m6.55% | Added +1.1m |
| TARSUS PHARMACEUTICALS INC TARS | $140.2m4.88% | Added +91.5k |
| EDGEWISE THERAPEUTICS INC EWTX | $120.0m4.17% | Added +1.7m |
| VAXCYTE INC PCVX | $116.5m4.05% | Added +795.1k |
| BEIGENE LTD ONC | $113.8m3.96% | Added +415.7k |
| CRINETICS PHARMACEUTICALS IN CRNX | $97.7m3.40% | Reduced -605.9k |
| MOONLAKE IMMUNOTHERAPEUTICS MLTX | $96.0m3.34% | Added +840.7k |
| DISC MEDICINE INC IRON | $95.0m3.30% | Unchanged |
| MERUS N V MRUS | $71.1m2.47% | Reduced -765.0k |
| VERA THERAPEUTICS INC VERA | $60.8m2.11% | Added +340.5k |
| APOGEE THERAPEUTICS INC COM | $58.2m2.02% | Added +581.9k |
| OLEMA PHARMACEUTICALS INC OLMA | $42.6m1.48% | Added +1.8m |
| PLIANT THERAPEUTICS INC PLRX | $42.1m1.46% | Added +92.6k |
| IMMATICS N.V IMTX | $38.5m1.34% | Added +1.5m |
| COGENT BIOSCIENCES INC COGT | $38.4m1.33% | Added +307.6k |
| SPYRE THERAPEUTICS INC SYRE | $35.6m1.24% | Added +259.6k |
| VIRIDIAN THERAPEUTICS INC VRDN | $34.9m1.21% | Reduced -1.1m |
| Y-MABS THERAPEUTICS INC YMAB | $33.2m1.15% | Added +150.0k |
| ERASCA INC ERAS | $27.0m0.94% | Added +84.2k |
| TECTONIC THERAPEUTIC INC TECX | $22.4m0.78% | New |
| LENZ THERAPEUTICS INC LENZ | $22.2m0.77% | New |
| SCHOLAR ROCK HLDG CORP SRRK | $17.3m0.60% | New |
| ORUKA THERAPEUTICS INC ORKA | $15.9m0.55% | Added +100.0k |
| AGIOS PHARMACEUTICALS INC AGIO | $9.1m0.32% | New |
Sold out since Q3 2024
| Security | Value then |
|---|---|
| KURA ONCOLOGY INC KURA | $84.6m4.3m shares |
| ARVINAS INC ARVN | $57.6m2.3m shares |
| IMMUNOVANT INC IMVT | $38.9m1.4m shares |
| CULLINAN THERAPEUTICS INC CGEM | $38.9m2.3m shares |
| KEROS THERAPEUTICS INC KROS | $30.5m525.0k shares |
| PERSPECTIVE THERAPEUTICS INC CATX | $12.3m919.7k shares |
| COMPASS PATHWAYS PLC CMPS | $7.3m1.2m shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 | 10.0%≈ $92.9m |
| EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 | 9.5%≈ $415.1m |
| ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 | 9.2%≈ $64.7m |
| ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 | 7.8%≈ $42.7m |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 6.1%≈ $123.5m |
| TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 | 5.8%≈ $110.9m |
| LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 | 5.3%≈ $19.4m |
| MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 | 5.2%≈ $137.6m |
| SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 | 5.1%≈ $395.7m |
| JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 | 5.1%≈ $69.0m |